Pharmaceutical Research Center: This application seeks to continue the evolution of the Pharmaceutical Research Center at Florida A&M University (FAMU). The previously funded targeted research activities have demonstrated productivity and resulted in significant discoveries that have led to the award of several patents and additional pending discoveries. Based on the evaluation of the current research infrastructure and the strategic needs of the program, it is proposed to transition the targeted activities into the development of Core research facilities. The main objective of the current application is to build the infrastructure of the research program towards more understanding of the mechanistic details of the molecular system. This RCMI center will focus efforts on approaches, i.e., gene expression analysis, proteomics, PCR analysis, gene delivery systems and DNA picroarray techniques. The establishment of Core facilities in the areas of molecular neurobiology, cellular imaging, neurochemistry/receptors, flow cytometry and nanomedicine will increase our abilities to understand the mechanistic details of the molecular system and to provide greater insights into how the different molecular are modulated under disease and adverse conditions. The Pharmaceutical Research Center will consist of a research administrative component coupled with four (4) core service delivery facilities. The administrative component will continue to provide pre- and post- award assistance, coordinate the activities of the external and internal advisory committee, provide scientific seminars and grants workshops, coordinate a new structured mentoring program, facilitate an extensive external evaluation of program outcomes, assist in faculty development, hire a research faculty member and market and conduct an on-site grants management workshop and the annual RCMI R01 Scientist Seminar Series.
Specific aim one (1) is to transition the program from the current research programs in neuroscience, drug delivery, and molecular biology to research cores focusing on Neurodegeneration research, Nanomedicine research, drug discovery and biotechnology: pathways to disease prevention and therapy. Through this network of Core facilities, the Pharmaceutical Research Center will foster inter- and inter-disciplinary research.
Aim two (2) is to increase research investigators capabilities and competitiveness to receive four (4) investigators initiated grants.
Aim three (3) is to assure the completion of program objectives and outcomes through a comprehensive formative and summative evaluation process.
Aim four (4) is to address health disparities through research emphasis on those conditions that adversely impact disadvantaged populations and produce additional minority scientists who will address disparities. This RCMI Program has been transformational at FAMU. Ensuring translational research is at the forefront of the proposed research activities as we seek to accelerate the utilization of our biomedical discoveries. The College's motto is """"""""Funding Cures and Saving Lives.""""""""

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Research Centers in Minority Institutions Award (G12)
Project #
5G12RR003020-27
Application #
8120820
Study Section
Special Emphasis Panel (ZRR1-RI-3 (01))
Program Officer
Douthard, Regine
Project Start
1997-08-01
Project End
2013-05-31
Budget Start
2011-06-01
Budget End
2012-05-31
Support Year
27
Fiscal Year
2011
Total Cost
$2,340,897
Indirect Cost
Name
Florida Agricultural and Mechanical University
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
623751831
City
Tallahassee
State
FL
Country
United States
Zip Code
32307
Poku, Rosemary A; Salako, Olufisayo O; Amissah, Felix et al. (2017) Polyisoprenylated cysteinyl amide inhibitors induce caspase 3/7- and 8-mediated apoptosis and inhibit migration and invasion of metastatic prostate cancer cells. Am J Cancer Res 7:1515-1527
Ntantie, Elizabeth; Fletcher, Jerrine; Amissah, Felix et al. (2017) Polyisoprenylated cysteinyl amide inhibitors disrupt actin cytoskeleton organization, induce cell rounding and block migration of non-small cell lung cancer. Oncotarget 8:31726-31744
Mazzio, Elizabeth A; Soliman, Karam F A (2017) HTP Nutraceutical Screening for Histone Deacetylase Inhibitors and Effects of HDACis on Tumor-suppressing miRNAs by Trichostatin A and Grapeseed (Vitis vinifera) in HeLa cells. Cancer Genomics Proteomics 14:17-33
Archibong, Edikan; Foster, Alexander; Caldwell, Keirsten et al. (2016) Synthesis, characterization, and electrospinning of novel polyaniline-peptide polymers. Appl Mater Today 4:78-82
Ofori, Edward; Zhu, Xue Y; Etukala, Jagan R et al. (2016) Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands. Bioorg Med Chem 24:3464-71
Mathis, Arlesia; Rooks, Ronica; Kruger, Daniel (2016) Improving the Neighborhood Environment for Urban Older Adults: Social Context and Self-Rated Health. Int J Environ Res Public Health 13:ijerph13010003
Godugu, Chandraiah; Doddapaneni, Ravi; Patel, Apurva R et al. (2016) Novel Gefitinib Formulation with Improved Oral Bioavailability in Treatment of A431 Skin Carcinoma. Pharm Res 33:137-54
Mochona, Bereket; Jackson, Timothy; McCauley, DeCoria et al. (2016) Synthesis and Cytotoxic Evaluation of Pyrrole Hetarylazoles Containing Benzimidazole/Pyrazolone/1,3,4-Oxadiazole Motifs. J Heterocycl Chem 53:1871-1877
Mazzio, Elizabeth A; Li, Nan; Bauer, David et al. (2016) Natural product HTP screening for antibacterial (E.coli 0157:H7) and anti-inflammatory agents in (LPS from E. coli O111:B4) activated macrophages and microglial cells; focus on sepsis. BMC Complement Altern Med 16:467
Etukala, Jagan R; Zhu, Xue Y; Eyunni, Suresh V K et al. (2016) Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores. Bioorg Med Chem 24:3671-9

Showing the most recent 10 out of 204 publications